The RVNC news page on Stock Titan provides an archive of announcements and transaction-related communications concerning Revance Therapeutics, Inc., a biotechnology company focused on aesthetic and therapeutic offerings. These news items document Revance’s role in the aesthetic injectables market, its product portfolio, and the corporate events that led to its acquisition by Crown Laboratories, Inc.
Readers can review press releases describing Crown’s commencement of a cash tender offer to acquire all outstanding shares of Revance, subsequent extensions of the tender offer, and an increase in the offer price that was unanimously approved by the Revance Board of Directors. Additional news items cover competing interest from Teoxane SA, reminders to Revance stockholders about tendering their shares, and joint announcements by Crown and Revance regarding the expiration of the tender offer and satisfaction of its conditions.
The archive also includes Crown’s announcements of the successful closing of the acquisition and completion of the second-step merger, in which Crown stated that Revance’s common stock will be delisted from the NASDAQ Global Select Market and deregistered. These releases provide context on how Revance, as the issuer of RVNC, transitioned from an independent publicly traded biotechnology company to a Crown-owned business within a larger skincare and aesthetics platform.
For investors and researchers, the RVNC news feed serves as a historical record of key milestones, including strategic reviews by the Revance Board, tender offer mechanics, and the ultimate outcome of the Crown transaction. Users interested in the evolution of Revance’s aesthetic and therapeutic portfolio, its partnerships with Teoxane SA, Viatris Inc., and Shanghai Fosun Pharmaceutical, and the terms of the acquisition can use this page to trace the sequence of public communications around the deal.
Revance Therapeutics (RVNC) reports a strong start for its DAXXIFY® PrevU program, with approximately 400 practices participating and positive patient feedback. Preliminary Q4 2022 revenue from DAXXIFY® is estimated between $10.5 million and $11.5 million, while RHA® Collection revenue shows impressive growth, projected at $34 million to $35 million, a 45% year-over-year increase. Full-year 2022 RHA® revenue is expected between $106.5 million and $107.5 million. Revance maintains its operating expense guidance and ends the year with around $340 million in cash and equivalents.
Revance Therapeutics announced that the FDA has accepted its supplemental Biologics License Application for DAXXIFY® (DaxibotulinumtoxinA-lanm) aimed at treating cervical dystonia. The PDUFA date is set for August 19, 2023. This treatment, noted for its long-lasting effects, was evaluated in two pivotal phase 3 studies showing significant efficacy with a median duration of effect of 24 weeks. The market for muscle movement disorders, including cervical dystonia, is nearing $1 billion in the U.S., indicating substantial business potential for Revance.
Revance Therapeutics (NASDAQ: RVNC) announced its participation in the 34th Annual Piper Sandler Healthcare Conference from November 29 to December 1, 2022, in New York City. CEO Mark J. Foley will present on November 29 at 10:00 AM ET. The live audio webcast will be accessible on the company’s Investor Relations webpage and will remain available for 90 days post-event. Revance focuses on innovative aesthetic and therapeutic products and is known for offerings like DAXXIFY™ and the RHA® Collection. The company also collaborates with Viatris to develop a biosimilar to BOTOX®.
Nanostics Inc. announced the appointment of Aubrey Rankin to its Board of Directors, succeeding Reg Joseph as an independent director. Rankin brings extensive experience in MedTech and FinTech, having formerly served as President of Innovation at Revance (Nasdaq: RVNC), where he integrated HintMD's patient-provider platform. His expertise is expected to aid in the launch of Nanostics' lead prostate cancer diagnostic, ClarityDX Prostate®, which uses a neural network algorithm to assess cancer risk based on biomarkers. The company expressed gratitude to Joseph for his contributions.
Revance Therapeutics (Nasdaq: RVNC) announced its participation in the Stifel 2022 Healthcare Conference on November 15-16, 2022, in New York City. CFO Tobin Schilke will present on November 15 at 3:00 p.m. ET. Interested investors can access the live audio webcast via the company's Investor Relations page at www.revance.com. The replay will be available for 30 days post-event. Revance is focused on innovative aesthetic and therapeutic solutions, including DAXXIFY™ and collaborations for BOTOX® biosimilars.
Revance Therapeutics, Inc. (RVNC) announced FDA approval for DAXXIFY™ to treat glabellar lines, marking a significant milestone. Q3 revenue reached $29.0 million, up 47% year-over-year, with RHA® Collection revenue at $26.1 million, also up 43%. The company completed a $230 million follow-on offering, ending Q3 with $378.6 million in cash and equivalents. Revance submitted an sBLA for DAXXIFY™ for cervical dystonia with a PDUFA target date in 2023. The call for Q3 results is scheduled for November 8, 2022.
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced the publication of two peer-reviewed articles in the Aesthetic Surgery Journal, focusing on injection techniques for treating glabellar lines. The studies emphasize the importance of precise interactions to optimize aesthetic results, highlighting the influence of injection techniques on eyebrow positioning. The first article evaluates how subtle differences in injection affect outcomes, while the second presents a systematic assessment algorithm for personalized treatments. This reflects Revance's ongoing commitment to enhancing patient care and outcomes in aesthetic treatments.
Revance Therapeutics, Inc. (Nasdaq: RVNC) will announce its third quarter 2022 financial results on November 8, 2022, after market close. A conference call and live webcast are scheduled for 4:30 p.m. ET the same day to discuss the results and provide updates on business and pipeline initiatives. Revance specializes in innovative aesthetic and therapeutic offerings, including the DAXXIFY™ injection and biosimilar development for BOTOX®. The call will be accessible via registration, with a replay available for 30 days post-call.
Revance Therapeutics has submitted a supplemental Biologics License Application (sBLA) to the FDA for DAXXIFY™ to treat cervical dystonia, a painful condition affecting neck muscles. The application is based on the ASPEN Phase 3 clinical program, showcasing DAXXIFY’s median response duration of 24 weeks. The company anticipates a PDUFA target action date in 2023. Successful approval could position Revance in the nearly $1 billion U.S. muscle movement disorder market, significantly reducing treatment frequency for patients.
Revance Therapeutics (RVNC) appointed Dr. David A. Hollander as Chief Medical Officer to enhance clinical development and regulatory strategies. This leadership change comes as the company prepares for the commercial launch of Daxxify™, recently approved by the FDA for glabellar lines, and the advancement of its biosimilar to Botox®. Dr. Hollander brings over 20 years of experience, having previously held prominent roles in R&D and regulatory affairs at Aerie Pharmaceuticals and Allergan. His extensive background is expected to bolster Revance's growth in aesthetics and therapeutics.